Drug Profile
Research programme: neurokinin-1 receptor antagonists - OPKO Health
Alternative Names: NK-1 antagonists - Schering-Plough; OPK 88002Latest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Schering-Plough
- Developer OPKO Health
- Class Antiemetics; Antipruritics
- Mechanism of Action Neurokinin 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chemotherapy-induced nausea and vomiting; Pruritus
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for preclinical development in Pruritus in USA
- 08 May 2018 OPKO Health plans a phase IIa trial of OPK 88002 for Pruritus in 2018
- 08 Aug 2017 OPKO Health's receives approval for an IND application for initiation of a phase IIa trial of OPK 88002 for Pruritus before August 2017